Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | S100A9 | P06702 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.44 |
| ▸ | HTR3B | O95264 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.44 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581044 | 0.85 | PNMT (0.54) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL294676 | 0.85 | PNMT (0.54) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL8370549 | 0.85 | PNMT (0.54) | PNMTTAAR1CYP3A4IDO1AGXT | |
| Hydrochloric Acid SCHEMBL28332854 | 0.83 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL2343233 | 0.83 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL30502958 | 0.83 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL2377117 | 0.82 | PNMT (0.50) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL1644190 | 0.82 | CA1 (0.57) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL2377120 | 0.82 | PNMT (0.50) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL9558316 | 0.80 | KMT2A (0.49) | PNMTTAAR1CYP3A4IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619095-B2 | Process for the preparation of indolone derivative | ALEMBIC LIMITED (IN) | 2009-11-17 | — | — | US | claimed |
| EP-1848691-B1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LTD (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | ALEMBIC LIMITED (IN) | 2008-10-23 | — | — | US | claimed |
| EP-1848691-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | Alembic Limited (IN) | 2007-10-31 | — | — | EP | claimed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | claimed |
| EP-0255134-B1 | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | claimed |
| EP-4400492-A1 | ACRIDINE COMPOUND | OSAKA UNIVERSITY (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| CN-118103359-A | Preparation method of eribulin derivative | 江苏恒瑞医药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117940408-A | Acridine compounds | 国立大学法人大阪大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20240132518-A1 | CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PREPARATION METHOD THEREFOR | SHANGHAI SENHUI MEDICINE CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| EP-0115334-A1 | Benzo-heterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-08 | — | — | EP | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132518-A1 | CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PREPARATION METHOD THEREFOR | WASF2, MRPL21, CLSPN | PNMT 3660/4885TAAR1 4877/4885CYP3A4 474/4885 |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PNMT 2104/4885TAAR1 690/4885CYP3A4 32/4885 |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | HTR3C, HTR3B, HTR1B | PNMT 112/4885TAAR1 833/4885CYP3A4 14/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | PNMT 4283/4885TAAR1 311/4885CYP3A4 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.